EICHORCondition: CLL/SLL · Sponsor: Ascentage Pharma Group Inc.
This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
This description comes directly from the study's public registry record.
Miguel Rosado-Cadena, MD · +1 301-532-7085 · miguel.cadena@ascentage.com
Jocelyn Budzynski · +1 301-693-6952 · jocelyn.budzynski@ascentage.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Anhui, China | Not Yet Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Nanfang Hospital of Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
| The affiliated Hospital of Guangdong Medical University | Zhanjiang, Guangdong, China | Not Yet Recruiting |
| Henan Provincial Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Not Yet Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| The Second Xiangya Hospital of Center South University | Changsha, Hunan, China | Not Yet Recruiting |
| Tongji Hospital of Tongji University | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Hematology Hospital of the Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06319456